Clinical use of lenvatinib in patients with previous renal and/or hepatic impairment and radioiodine‐refractory differentiated thyroid cancer
Open Access
- 6 October 2022
- journal article
- review article
- Published by Wiley in Cancer Medicine
- Vol. 11 (S1) , 5-9
Abstract
Lenvatinib is one the most active drugs in radioiodine‐refractory differentiated thyroid cancer (RR‐DTC) such that it has become an important therapeutic tool in tumor control and survival. Renal and hepatic impairments are common comorbidities in cancer patients. Treating these patients is a challenge that requires careful consideration. As a first approach to patients with RR‐DTC and renal or hepatic impairment, Summary of Product Characteristics recommendations for lenvatinib use and dose adjustments should be strictly followed. Close clinical and blood monitoring is the gold standard approach to optimizing lenvatinib's use during the whole course of treatment.Keywords
This publication has 20 references indexed in Scilit:
- A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid CancerClinical Cancer Research, 2016
- Feasibility, Efficacy and Safety of Tyrosine Kinase Inhibitor Treatment in Hemodialyzed Patients with Renal Cell Cancer: 10 Years of ExperienceFuture Oncology, 2015
- Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN)Annals of Oncology, 2015
- Liver Cirrhosis: Evaluation, Nutritional Status, and PrognosisMediators of Inflammation, 2015
- Pharmacokinetics and excretion of 14C-lenvatinib in patients with advanced solid tumors or lymphomasInvestigational New Drugs, 2014
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trialThe Lancet, 2014
- Annual Report to the Nation on the status of cancer, 1975‐2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancerCancer, 2013
- Papillary Thyroid Cancer: Time Course of Recurrences During Postsurgery SurveillanceThe Journal of Clinical Endocrinology & Metabolism, 2013
- Epidemiology of Chronic Kidney Disease in Cancer Patients: Lessons From the IRMA Study GroupSeminars in Nephrology, 2010
- Pharmacokinetics and dosage adjustment in patients with hepatic dysfunctionEuropean Journal of Clinical Pharmacology, 2008